Developer docs
API playgroundTry for free, no card

Search company profiles

Stoke Therapeutics

Full company profile

uuid00009oz

Namestring
Stoke Therapeutics
Legal namestring
Stoke Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Stoke Therapeutics is a clinical-stage biotechnology company developing antisense oligonucleotide (ASO) medicines based on its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which modulates pre-mRNA splicing to increase protein output from healthy gene copies in autosomal dominant haploinsufficiency diseases. The company's lead candidate, zorevunersen (STK-001), targets Dravet syndrome by increasing SCN1A gene expression and is in Phase 3 development (EMPEROR study) under FDA Breakthrough Therapy Designation, with a rolling NDA submission planned for H1 2027 and data readout anticipated mid-2027. A second clinical candidate, STK-002, is in a Phase 1 dose-escalation study (OSPREY) for Autosomal Dominant Optic Atrophy, and an exploratory program targets SYNGAP1-related intellectual disability. The TANGO bioinformatics pipeline has identified approximately 1,200 monogenic diseases and approximately 6,500 additional genes as amenable to the platform, creating a broad pipeline optionality.

Stoke is a pre-commercial company that reported $184.42 million in FY2025 revenue, all derived from contractual arrangements with Biogen (global zorevunersen commercialization rights outside the US, Canada, and Mexico) and Acadia Pharmaceuticals, rather than product sales. The company retains exclusive US, Canada, and Mexico commercialization rights for zorevunersen and plans a direct field sales effort targeting specialized epilepsy treatment centers. Pricing for zorevunersen has not been publicly disclosed, though one analyst has modeled a $600,000 per year net price and projected peak annual US sales exceeding $1.5 billion.

The company is publicly traded on NASDAQ under ticker STOK, headquartered in Bedford, Massachusetts with a planned 2026 relocation to a triple-sized facility in Waltham, Massachusetts. It is led by CEO Ian F. Smith (appointed permanently in October 2024), with co-founders Adrian Krainer (Wolf Prize laureate, inventor of Spinraza) and Isabel Aznarez providing scientific leadership. As of December 31, 2025, Stoke held approximately $391.7 million in cash, expected to fund operations into 2028, and had a market capitalization of approximately $1.8 billion.

Short descriptiontext

Stoke Therapeutics is a clinical-stage biotech developing antisense oligonucleotide medicines using its proprietary TANGO platform to treat genetic haploinsufficiency diseases, with its lead candidate zorevunersen in Phase 3 for Dravet syndrome and partnered globally with Biogen.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBedford, United States
HQ citystring
Bedford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense oligonucleotide therapeutics, RNA-based medicines, rare disease therapeutics, genetic disease treatments, haploinsufficiency drug development
Industry3 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
RNA-based antisense oligonucleotide therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Revenue
TypeLicensing Royalties
Description

Stoke Therapeutics is a development-stage company with no approved products or current commercial revenue. It recognizes revenue from contractual partnerships with Biogen and Acadia Pharmaceuticals — in Q3 2025, the company reported $10.6 million in revenue from these arrangements.

simplywall.st
2Public Offering (Equity Financing)
TypeSubscription Recurring
Description

Stoke raised $125 million through an upsized public offering of common stock and pre-funded warrants in March/April 2024 to fund research, clinical development, and manufacturing of its RNA-based medicines.

biospace.com
3Future Product Revenue (Projected)
TypeSubscription Recurring
Description

If zorevunersen is approved, Stoke retains US, Canada, and Mexico commercialization rights while Biogen holds rest-of-world rights. Peak annual sales are projected by analysts to exceed $1.5 billion in the US market alone.

finance.yahoo.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Stoke Therapeutics develops antisense oligonucleotide (ASO) medicines that use its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to restore missing proteins by upregulating protein output from healthy gene copies in diseases caused by haploinsufficiency. Its lead candidate zorevunersen (STK-001) is in Phase 3 development for Dravet syndrome, with a second candidate STK-002 in Phase 1 for Autosomal Dominant Optic Atrophy (ADOA).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 85% seizure reduction observed in zorevunersen-treated patients in Phase 1/2a studies
+4 more records
Product overview1 text field

Stoke Therapeutics is developing a portfolio of antisense oligonucleotide (ASO) medicines based on its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. The lead product is zorevunersen (STK-001), an ASO for Dravet syndrome currently in Phase 3 development with Breakthrough Therapy Designation, developed in partnership with Biogen for global commercialization rights outside the US, Canada, and Mexico. The second product candidate is STK-002, an ASO for Autosomal Dominant Optic Atrophy (ADOA) in Phase 1 trials. The company is also exploring TANGO for SYNGAP1 and other diseases. The TANGO platform enables selective upregulation of protein expression to address genetic diseases caused by haploinsufficiency.

Product and service2 records
1Zorevunersen (STK-001)
CategoryCore Drug Candidate / Antisense Oligonucleotide Therapy
Description

Investigational antisense oligonucleotide (ASO) medicine designed to target the underlying genetic cause of Dravet syndrome by increasing protein expression from the SCN1A gene. Currently in Phase 3 EMPEROR clinical study with FDA Breakthrough Therapy Designation, and being co-developed with Biogen (which holds ex-US/Canada/Mexico commercialization rights) for use in patients with this severe developmental and epileptic encephalopathy.

2STK-002
CategoryCore Drug Candidate / Antisense Oligonucleotide Therapy
Description

Investigational antisense oligonucleotide therapy targeting OPA1 gene variants for Autosomal Dominant Optic Atrophy (ADOA), a rare genetic disease causing progressive and irreversible vision loss. Currently in Phase 1 OSPREY study evaluating safety and tolerability in patients ages 6 to 55 with confirmed OPA1 gene variants.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Strategic collaboration for zorevunersen (STK-001) for Dravet syndrome. Stoke retains exclusive US, Canada, and Mexico commercialization rights; Biogen holds commercialization rights for the rest of the world. The partnership includes co-development, shared clinical costs, and milestone payments. Biogen has participated in data presentation (NEJM publication March 2026) and jointly presents at scientific conferences.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Stoke recognized $10.6 million in revenue from contractual obligations with Acadia Pharmaceuticals in Q3 2025, suggesting a separate collaboration or licensing arrangement, though details are not extensively disclosed.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusively licensed foundational TANGO patents from Cold Spring Harbor Laboratory. Adrian Krainer serves as St. Giles Foundation Professor at Cold Spring Harbor Laboratory Cancer Center and is a co-founder of Stoke Therapeutics.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusively licensed foundational TANGO patents from the University of Southampton, alongside Cold Spring Harbor Laboratory patents, forming the core IP estate for the TANGO platform.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ionis is the pioneer and leader in antisense oligonucleotide therapeutics, with approved drugs including Spinraza (developed by Stoke co-founder Krainer). Both companies target CNS and rare genetic diseases using ASO chemistry, making Ionis the closest direct comparable.

TypeDirect peer
Description

Biogen is Stoke's commercial partner for zorevunersen ex-US and the originator of Spinraza, the first approved CNS ASO. Biogen shares deep CNS/neurology rare disease expertise and is the natural benchmark for ASO commercialization economics.

TypeDirect peer
Description

Sarepta develops genetic medicines for rare neuromuscular diseases including Duchenne muscular dystrophy. Both companies pursue disease-modifying therapies for severe genetic conditions via novel modalities and rare disease commercial models.

TypeDirect peer
Description

Wave develops stereopure oligonucleotide therapeutics (ASOs and siRNA) targeting rare genetic neurological diseases including Dravet syndrome and Huntington's disease, directly competing with Stoke's TANGO platform in adjacent CNS indications.

TypeDirect peer
Description

Alnylam is the leading RNAi therapeutics company developing siRNA drugs for rare genetic diseases. While chemically distinct from ASOs, both companies use oligonucleotide-based platforms to silence or modulate gene expression in genetically defined patient populations.

6Avidity Biosciences
TypeDirect peer
Description

Avidity develops antibody-RNA conjugates for rare neuromuscular diseases, with deep ties to Stoke through board member Arthur Levin (former Avidity CSO) and Stoke co-founders. Both target rare genetic conditions with RNA-based modalities.

TypeEmerging player
Description

Solid Biosciences develops genetic medicines for Duchenne muscular dystrophy and other rare diseases. Board overlap (Julie Anne Smith, Ian Smith) and shared rare disease focus make Solid a comparable emerging rare disease genetic medicine player.

TypeBroad incumbent
Description

Moderna is a leading mRNA therapeutics company with Stoke CMO Barry Ticho previously serving as Head of R&D. While broader in scope, Moderna represents an incumbent RNA therapeutics platform competing for talent, partnerships, and pipeline assets in the genetic medicine space.

TypeBroad incumbent
Description

Pfizer is a broad pharmaceutical incumbent with active ASO and rare disease programs, including board member Clare Kahn's prior leadership roles. Pfizer represents the large-cap benchmark for rare disease commercialization, pricing, and competitive dynamics.

TypeEmerging player
Description

Voyager develops gene therapies for neurological diseases including CNS indications. Stoke's Chief Regulatory Officer Beth Mellen previously served at Voyager. Both are early-stage CNS genetic medicine companies competing for talent and partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stoke Therapeutics

RNA-based antisense oligonucleotide therapeuticsstoketherapeutics.com

Stoke Therapeutics is a clinical-stage biotech developing antisense oligonucleotide medicines using its proprietary TANGO platform to treat genetic haploinsufficiency diseases, with its lead candidate zorevunersen in Phase 3 for Dravet syndrome and partnered globally with Biogen.

What Stoke Therapeutics does

Stoke Therapeutics is a clinical-stage biotechnology company developing antisense oligonucleotide (ASO) medicines based on its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which modulates pre-mRNA splicing to increase protein output from healthy gene copies in autosomal dominant haploinsufficiency diseases. The company's lead candidate, zorevunersen (STK-001), targets Dravet syndrome by increasing SCN1A gene expression and is in Phase 3 development (EMPEROR study) under FDA Breakthrough Therapy Designation, with a rolling NDA submission planned for H1 2027 and data readout anticipated mid-2027. A second clinical candidate, STK-002, is in a Phase 1 dose-escalation study (OSPREY) for Autosomal Dominant Optic Atrophy, and an exploratory program targets SYNGAP1-related intellectual disability. The TANGO bioinformatics pipeline has identified approximately 1,200 monogenic diseases and approximately 6,500 additional genes as amenable to the platform, creating a broad pipeline optionality.

Stoke is a pre-commercial company that reported $184.42 million in FY2025 revenue, all derived from contractual arrangements with Biogen (global zorevunersen commercialization rights outside the US, Canada, and Mexico) and Acadia Pharmaceuticals, rather than product sales. The company retains exclusive US, Canada, and Mexico commercialization rights for zorevunersen and plans a direct field sales effort targeting specialized epilepsy treatment centers. Pricing for zorevunersen has not been publicly disclosed, though one analyst has modeled a $600,000 per year net price and projected peak annual US sales exceeding $1.5 billion.

The company is publicly traded on NASDAQ under ticker STOK, headquartered in Bedford, Massachusetts with a planned 2026 relocation to a triple-sized facility in Waltham, Massachusetts. It is led by CEO Ian F. Smith (appointed permanently in October 2024), with co-founders Adrian Krainer (Wolf Prize laureate, inventor of Spinraza) and Isabel Aznarez providing scientific leadership. As of December 31, 2025, Stoke held approximately $391.7 million in cash, expected to fund operations into 2028, and had a market capitalization of approximately $1.8 billion.

Stoke Therapeutics firmographics

Firmographics
Name
Stoke Therapeutics
Legal name
Stoke Therapeutics, Inc.
Website
https://stoketherapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Stoke Therapeutics is a clinical-stage biotech developing antisense oligonucleotide medicines using its proprietary TANGO platform to treat genetic haploinsufficiency diseases, with its lead candidate zorevunersen in Phase 3 for Dravet syndrome and partnered globally with Biogen.
Ownership category
akta.pro rank

Stoke Therapeutics industry classification

Industry
Product category
RNA-based antisense oligonucleotide therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Antisense oligonucleotide therapeutics
  • RNA-based medicines
  • Rare disease therapeutics
  • Genetic disease treatments
  • Haploinsufficiency drug development

Where Stoke Therapeutics is headquartered

Location

Headquarters

HQ city
Bedford
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Stoke Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Contract Revenue: Stoke Therapeutics is a development-stage company with no approved products or current commercial revenue. It recognizes revenue from contractual partnerships with Biogen and Acadia Pharmaceuticals — in Q3 2025, the company reported $10.6 million in revenue from these arrangements.
  2. Public Offering (Equity Financing): Stoke raised $125 million through an upsized public offering of common stock and pre-funded warrants in March/April 2024 to fund research, clinical development, and manufacturing of its RNA-based medicines.
  3. Future Product Revenue (Projected): If zorevunersen is approved, Stoke retains US, Canada, and Mexico commercialization rights while Biogen holds rest-of-world rights. Peak annual sales are projected by analysts to exceed $1.5 billion in the US market alone.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Stoke Therapeutics product offering

Product offering

Core offering

Stoke Therapeutics develops antisense oligonucleotide (ASO) medicines that use its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to restore missing proteins by upregulating protein output from healthy gene copies in diseases caused by haploinsufficiency. Its lead candidate zorevunersen (STK-001) is in Phase 3 development for Dravet syndrome, with a second candidate STK-002 in Phase 1 for Autosomal Dominant Optic Atrophy (ADOA).

Product overview

Stoke Therapeutics is developing a portfolio of antisense oligonucleotide (ASO) medicines based on its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. The lead product is zorevunersen (STK-001), an ASO for Dravet syndrome currently in Phase 3 development with Breakthrough Therapy Designation, developed in partnership with Biogen for global commercialization rights outside the US, Canada, and Mexico. The second product candidate is STK-002, an ASO for Autosomal Dominant Optic Atrophy (ADOA) in Phase 1 trials. The company is also exploring TANGO for SYNGAP1 and other diseases. The TANGO platform enables selective upregulation of protein expression to address genetic diseases caused by haploinsufficiency.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zorevunersen (STK-001) Investigational antisense oligonucleotide (ASO) medicine designed to target the underlying genetic cause of Dravet syndrome by increasing protein expression from the SCN1A gene. Currently in Phase 3 EMPEROR clinical study with FDA Breakthrough Therapy Designation, and being co-developed with Biogen (which holds ex-US/Canada/Mexico commercialization rights) for use in patients with this severe developmental and epileptic encephalopathy.
  • STK-002 Investigational antisense oligonucleotide therapy targeting OPA1 gene variants for Autosomal Dominant Optic Atrophy (ADOA), a rare genetic disease causing progressive and irreversible vision loss. Currently in Phase 1 OSPREY study evaluating safety and tolerability in patients ages 6 to 55 with confirmed OPA1 gene variants.

Quantifiable outcome

  • Up to 85% seizure reduction observed in zorevunersen-treated patients in Phase 1/2a studies
  • +4 more outcomes

Companies that use Stoke Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Stoke Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Stoke Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, minor and core.

  • BiogenflagshipStrategic or Co-development Partner · 1 January 2020Strategic collaboration for zorevunersen (STK-001) for Dravet syndrome. Stoke retains exclusive US, Canada, and Mexico commercialization rights; Biogen holds commercialization rights for the rest of the world. The partnership includes co-development, shared clinical costs, and milestone payments. Biogen has participated in data presentation (NEJM publication March 2026) and jointly presents at scientific conferences.
  • Acadia PharmaceuticalsminorStrategic or Co-development PartnerStoke recognized $10.6 million in revenue from contractual obligations with Acadia Pharmaceuticals in Q3 2025, suggesting a separate collaboration or licensing arrangement, though details are not extensively disclosed.
  • Cold Spring Harbor LaboratorycoreTechnology or IntegrationExclusively licensed foundational TANGO patents from Cold Spring Harbor Laboratory. Adrian Krainer serves as St. Giles Foundation Professor at Cold Spring Harbor Laboratory Cancer Center and is a co-founder of Stoke Therapeutics.
  • University of SouthamptoncoreTechnology or IntegrationExclusively licensed foundational TANGO patents from the University of Southampton, alongside Cold Spring Harbor Laboratory patents, forming the core IP estate for the TANGO platform.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Stoke Therapeutics competitors and assessment

Company assessment

Direct peers

  • Ionis Pharmaceuticals: Ionis is the pioneer and leader in antisense oligonucleotide therapeutics, with approved drugs including Spinraza (developed by Stoke co-founder Krainer). Both companies target CNS and rare genetic diseases using ASO chemistry, making Ionis the closest direct comparable.
  • Biogen: Biogen is Stoke's commercial partner for zorevunersen ex-US and the originator of Spinraza, the first approved CNS ASO. Biogen shares deep CNS/neurology rare disease expertise and is the natural benchmark for ASO commercialization economics.
  • Sarepta Therapeutics: Sarepta develops genetic medicines for rare neuromuscular diseases including Duchenne muscular dystrophy. Both companies pursue disease-modifying therapies for severe genetic conditions via novel modalities and rare disease commercial models.
  • Wave Life Sciences: Wave develops stereopure oligonucleotide therapeutics (ASOs and siRNA) targeting rare genetic neurological diseases including Dravet syndrome and Huntington's disease, directly competing with Stoke's TANGO platform in adjacent CNS indications.
  • Alnylam Pharmaceuticals: Alnylam is the leading RNAi therapeutics company developing siRNA drugs for rare genetic diseases. While chemically distinct from ASOs, both companies use oligonucleotide-based platforms to silence or modulate gene expression in genetically defined patient populations.
  • Avidity Biosciences: Avidity develops antibody-RNA conjugates for rare neuromuscular diseases, with deep ties to Stoke through board member Arthur Levin (former Avidity CSO) and Stoke co-founders. Both target rare genetic conditions with RNA-based modalities.

Emerging players

  • Solid Biosciences: Solid Biosciences develops genetic medicines for Duchenne muscular dystrophy and other rare diseases. Board overlap (Julie Anne Smith, Ian Smith) and shared rare disease focus make Solid a comparable emerging rare disease genetic medicine player.
  • Voyager Therapeutics: Voyager develops gene therapies for neurological diseases including CNS indications. Stoke's Chief Regulatory Officer Beth Mellen previously served at Voyager. Both are early-stage CNS genetic medicine companies competing for talent and partnerships.

Broad incumbents

  • Moderna: Moderna is a leading mRNA therapeutics company with Stoke CMO Barry Ticho previously serving as Head of R&D. While broader in scope, Moderna represents an incumbent RNA therapeutics platform competing for talent, partnerships, and pipeline assets in the genetic medicine space.
  • Pfizer: Pfizer is a broad pharmaceutical incumbent with active ASO and rare disease programs, including board member Clare Kahn's prior leadership roles. Pfizer represents the large-cap benchmark for rare disease commercialization, pricing, and competitive dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Stoke Therapeutics social profiles

Digital presence

Stoke Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stoke Therapeutics leadership team

Management profile

Number of profiles

Profiles19 records

Stoke Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stoke Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stoke Therapeutics

What does Stoke Therapeutics do?

Stoke Therapeutics develops antisense oligonucleotide (ASO) medicines that use its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to restore missing proteins by upregulating protein output from healthy gene copies in diseases caused by haploinsufficiency. Its lead candidate zorevunersen (STK-001) is in Phase 3 development for Dravet syndrome, with a second candidate STK-002 in Phase 1 for Autosomal Dominant Optic Atrophy (ADOA).

Is Stoke Therapeutics a public or private company?

Stoke Therapeutics is a public company. It is classified as public and is currently operating.

When was Stoke Therapeutics founded?

Stoke Therapeutics was founded in 2015. It employs 101 to 250 people.

Where is Stoke Therapeutics based?

Stoke Therapeutics is headquartered in Bedford, United States, in the North America region.

How does Stoke Therapeutics make money?

Three revenue lines are on record. Contract Revenue is the primary driver. The others are public Offering (Equity Financing) and future Product Revenue (Projected).

Who are Stoke Therapeutics's main competitors?

Direct peers on record are Ionis Pharmaceuticals, Biogen, Sarepta Therapeutics, Wave Life Sciences, Alnylam Pharmaceuticals and Avidity Biosciences. Emerging players are Solid Biosciences and Voyager Therapeutics. Broad incumbents are Moderna and Pfizer.

Does Stoke Therapeutics have an API?

No public API is recorded for Stoke Therapeutics.

What industry is Stoke Therapeutics in?

Stoke Therapeutics's product category is RNA-based antisense oligonucleotide therapeutics. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsStoke Therapeutics, Inc. $STOK Stock Bought by Alps Advisors Inc.Alps Advisors increased its stake in Stoke Therapeutics by 35.7% in Q3, holding 85,483 shares worth $2.22 million. Analysts have a consensus "Moderate Buy" rating with an average target price of $44.17, while insiders sold 27,418 shares over the last quarter.American Banking and Market NewsHead to Head Analysis: MannKind (NASDAQ:MNKD) & Stoke Therapeutics (NASDAQ:STOK)MannKind and Stoke Therapeutics are compared on profitability, valuation, and analyst ratings. MannKind has higher revenue ($348.97M vs $184.42M) and a lower P/E ratio, with a consensus target price of $8.33 implying 98.89% upside. Stoke's target is $44.17, implying 59.39% upside.Seeking AlphaStoke Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:STOK) 2026-11-03Stoke Therapeutics reported Q3 2026 EPS of -$1.08, missing by $0.17, while revenue of $11.26M beat by $3.07M. The stock closed at $27.40, up 3.47%, with a market cap of $1.72B.Business Wire BlogStoke Therapeutics to Present at Upcoming Investor Conferences in NovemberStoke Therapeutics announced CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Guggenheim Healthcare Innovation Conference in Boston on November 10 and the Jefferies London Global Healthcare Conference on November 17. The company's lead drug zorevunersen, an antisense oligonucleotide for Dravet syndrome, is in Phase 3 development with orphan drug designations.Stock TitanStoke Therapeutics to present at two investor conferencesStoke Therapeutics announced that CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Guggenheim Healthcare Innovation Conference in Boston on November 10, 2026, and the Jefferies London Global Healthcare Conference on November 17, 2026. The company's lead drug zorevunersen, for Dravet syndrome, is in Phase 3 development.Simply Wall StLearn Why The Bull Case For Stoke Therapeutics Stock Could Change Following Phase III Trial ProgressStoke Therapeutics reported Q3 2026 sales of $11.26 million and a net loss of $73.64 million. Management reiterated the Phase III EMPEROR trial data expected in Q3 2027 and a potential U.S. filing in 2027. Analysts project revenues of $177.8 million and earnings of $33.6 million by 2029.YahooStoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn QuestionStoke Therapeutics' stock fell 0.2% to $26.29 after Q3 2026 results, with revenue of $11.26 million and a net loss of $73.64 million, widening 92% year-over-year. The company's Dravet platform remains in development, with Phase III data pending and no near-term profit expected.MarketBeatStoke Therapeutics (NASDAQ:STOK) Announces Quarterly Earnings ResultsStoke Therapeutics reported Q2 EPS of -$1.08, missing the -$0.93 consensus, with revenue of $11.26 million versus an $8.21 million estimate. The company expects topline data from its EMPEROR Phase III trial in Q3 2027 and is preparing for a potential zorevunersen launch in early 2028.Business Wire BlogStoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesStoke Therapeutics reported Q3 2026 results with a $73.6M net loss and $358.8M in cash, funding operations into early 2028. The Phase 3 EMPEROR study of zorevunersen for Dravet syndrome is on track, with data readout expected in Q3 2027 and NDA submission in H2 2027. The company also advanced STK-002 for ADOA.Investing.comStoke Therapeutics earnings: Investors brace for revenue testStoke Therapeutics will report Q3 earnings Thursday, with analysts expecting a 93-cent loss on $8.21 million revenue, down 12% sequentially. The company plans a Phase 3 readout for zorevunersen in Q3 2027 and an NDA submission in H2 2027. Wall Street remains bullish, with all 14 analysts rating it a Strong Buy.